Results for immunoglobulin translation from Greek to English

human cytomegalovirus immunoglobulin i. v.
human cytomegalovirus immunoglobulin i. v.

human varicella- zoster immunoglobulin i. v.
human varicella-zoster immunoglobulin i. v.

human tick- borne encephalitis immunoglobulin i. m.
human tick-borne encephalitis immunoglobulin i. m.

core spc for human normal immunoglobulin for subcutaneous and intramuscular use
core spc for human normal immunoglobulin for subcutaneous and intramuscular use

immunoglobulin for intravenous and/ or intramuscular use core spc for human normal
core spc for human and anti-d immunoglobulin for intravenous and/or intramuscular use adopted june 2000

immunoglobulin for intravenous and/ or intramuscular use note for guidance on the clinical
note for guidance on the clinical investigation of human anti-d immunoglobulin for intravenous and/or intramuscular use adopted june 2000

immunoglobulin for intravenous administration (ivig) core spc for human and anti- d
note for guidance on the clinical investigation of human normal immunoglobulin for intravenous administration (ivig) adopted june 2000

note for guidance on the clinical investigation of human normal immunoglobulin for subcutaneous and intramuscular use
note for guidance on the clinical investigation of human normal immunoglobulin for subcutaneous and intramuscular use

Τίτλος εγγράφου note for guidance on the clinical investigation of human normal immunoglobulin for subcutaneous and intramuscular use
note for guidance on the clinical investigation of human released for consultation march 2001 normal immunoglobulin for subcutaneous and intramuscular use

core summary of product characteristics for hepatitis b immunoglobulin revision of core summary of product characteristics for human normal immunoglobulin for intravenous use – addition of indication for treatment of parvovirus b19 infection revision of core summary of product characteristics for human plasma derived factor vii products and human plasma prothrombin complex revision of core summary of product characteristics for factor viii inhibitor bypassing fraction warning on transmissible agents for patient leaflets and summary of product characteristics revision of core summary of product characteristics for human anti- d immunoglobulin for intravenous and/ or intramuscular use (cpmp/ bpwg/ 574/ 99)
core summary of product characteristics for hepatitis b immunoglobulin revision of core summary of product characteristics for human normal immunoglobulin for intravenous use – addition of indication for treatment of parvovirus b19 infection revision of core summary of product characteristics for human plasma derived factor vii products and human plasma prothrombin complex revision of core summary of product characteristics for factor viii inhibitor bypassing fraction warning on transmissible agents for patient leaflets and summary of product characteristics revision of core summary of product characteristics for human anti-d immunoglobulin for intravenous and/ or intramuscular use (cpmp/ bpwg/ 574/ 99)